awmsg logo



rilpivirine (Edurant®)


Reference No. 2936

Publication date:
05/10/2016


Appraisal information

rilpivirine (Edurant®) 25 mg film-coated tablet


Company: Janssen-Cilag Ltd
BNF category: Infections
NMG meeting date: 20/07/2016
AWMSG meeting date: 21/09/2016
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2616
Ministerial ratification: 04/10/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Rilpivirine (Edurant®) is recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive patients from 12 years old to < 18 years old with a viral load ≤ 100,000 HIV-1 RNA copies/ml.
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download
Final Appraisal Recommendation (FAR)
Download